Effect of autotransfusion system on tumor recurrence and survival in hepatocellular carcinoma patients

Table 1 Clinical and demographic characteristics of 83 hepatocellular carcinoma patients undergoing liver transplantation with and without continuous autotransfusion system n (%)

Patient Characteristics	CATS group (n = 24)	Non-CATS group (n = 59)	P
Sex
Male	22 (91.7)	52 (88.1)	0.6
Female	2 (8.3)	7 (11.9)
Age, yr
mean ± SE	52.0 ± 1.8	51.0 ± 1.2	0.7
Median (range)	54 (37-67)	53 (18-69)
BMI, kg/m2	25.5 ± 0.8	25.1 ± 0.6	0.8
Underlying disease
HBV	18 (75)	39 (66)	0.2
HBV + HCV	0	1 (1.7)
HBV + HDV	5 (20.8)	9 (15.3)
HCV	0	5 (8.5)
Primary HCC	0	5 (8.5)
Wilson	1 (4.2)	0
Donor type
Living	24 (100)	56 (95)	0.1
Deceased	0	3 (5)
GRWR	1.10 ± 0.06	1.20 ± 0.05	0.9
Child score
A	6 (25.0)	18 (30.5)	0.7
B	11 (45.8)	29 (49.2)
C	7 (29.2)	12 (20.3)
MELD score	14.5 ± 0.9	13.6 ± 0.8
Current status
Alive	13 (54.2)	41 (69.5)	0.2
Mortality	11 (45.8)	18 (30.5)
Hospital stay, d (range)	35.0 ± 13.8 (14-69)	33.0 ± 38.2 (7-274)	0.6
Follow-up, mo (range)	25.8 ± 15.1 (4-53)	17.9 ± 12.8 (4-56)

HBV: Hepatitis B virus; HCV: Hepatitis C virus; CATS: Continuous autotransfusion system; BMI: Body mass index; HCC: Hepatocellular carcinoma; CATS: Continuous autotransfusion system; GRWR: Graft-to-recipient weight ratio; MELD: Model for End-Stage Liver Disease.

Table 2 Detailed tumor characteristics of liver-transplanted hepatocellular carcinoma patients in the continuous autotransfusion system and non-continuous autotransfusion system groups n (%)

Tumor characteristics	CATS group (n = 24)	Non-CATS group (n = 59)	P value
Tumor count
< 10	17 (70.8)	47 (79.6)	0.4
> 10	7 (29.2)	12 (20.3)
Mean tumor size, cm	5.8 ± 0.9	5.2 ± 0.5	0.7
Milan criteria
Within	8 (33.3)	22 (37.3)	0.7
Beyond	16 (66.6)	37 (62.7)
UCSF criteria
Within	9 (37.5)	29 (49.2)	0.3
Beyond	15 (62.5)	30 (50.8)
AFP levels
< 200	17 (70.8)	43 (73)	0.7
> 200	7 (29.2)	16 (27)
Tumor differentiation
Good	12 (50.0)	24 (41.0)	0.6
Average	9 (37.5)	23 (39.0)
Poor	3 (12.5)	12 (20.0)
Macrovascular invasion
Present	2 (8.4)	3 (5.0)	0.6
Absent	22 (91.6)	56 (95.0)
HCC recurrence
Present	7 (29.2)	15 (25.4)	0.7
Absent	17 (70.8)	44 (74.6)
Recurrence and/or metastasis
Hepatic	2	3	0.8
Extrahepatic	1	2
Both	4	10
Recurrence site
Liver	2	3
Lung	0	2
Liver + bone	1	0
Liver + lung	1	1
Liver + stomach	1	0
Liver + bone + lung	1	0
Lung + surrenal gland	1	0
Liver + surrenal gland	0	4
Liver + surrenal gland + lung	0	2	0
Liver + esophagus	0	1
Liver + lung + brain	0	1
Liver + surrenal gland + peritoneum	0	1

UCSF: University of California San Francisco; CATS: Continuous autotransfusion system; AFP: Alpha-fetoprotein; HCC: Hepatocellular carcinoma.